Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Biogen wins FDA approval on new multiple sclerosis drug

By , Globe Staff

The drug is for patients whose multiple sclerosis relapses aren’t sufficiently controlled by existing therapies.

Thermo Fisher Scientific to buy FEI for $4.2 billion

By , Globe Staff

The purchase of FEI, which has more than 3,000 employees globally, is Thermo Fisher’s second-largest acquisition.

Sarepta’s stock soars after FDA postpones vote

By , Globe Staff

Investors saw the delay as a sign the Food and Drug Administration might approve the company’s drug to treat Duchenne muscular dystrophy.

Mass Innovation Labs targets smaller startups

By , Globe Staff

The Cambridge operator of biotech research space is preparing to add six new “innovation suites” for smaller companies.